Oncology News | pharmaphorum

News

Eli Lilly withdraws cancer drug Lartruvo from all markets

Eli Lilly is to withdraw its cancer drug Lartruvo from all markets after a late-stage trial showed it did not improve survival, although existing patients can continue receive it under an a

News

Psoriasis and cardio drugs drive Novartis' Q1 sales

Novartis has begun 2019 at a sprint, upgrading its sales forecasts for the year after strong performances from psoriasis drug Cosentyx and cardiology medicine Entresto.

News

Clovis hit by bladder cancer fail for Rubraca

Clovis Oncology’s hopes of a carving out a niche for its PARP inhibitor Rubraca in bladder cancer, away from its rivals in the class, have hit a setback.

News

J&J gets US okay for first targeted bladder cancer drug

Johnson & Johnson’s Balversa has become the first targeted therapy for bladder cancer after an FDA approval at the tail end of last week for patients with mutations in the FGFR gene.

News

Janssen J&J Johnson and Johnson pharmaceutical companies

EU regulators to fast-track Janssen's multiple myeloma CAR-T

European regulators are to hasten development of Janssen’s CAR-T therapy for patients with multiple myeloma, after promising early-stage trial results.

News

Fusion raises $105m for radiopharmaceutical trials

Radiopharmaceuticals are already well established in imaging technology for a range of diseases – but their use to deliver a lethal dose of radiation to cancer cells is also gaining increas

Eli Lilly withdraws cancer drug Lartruvo from all markets

Psoriasis and cardio drugs drive Novartis' Q1 sales

Clovis hit by bladder cancer fail for Rubraca

J&J gets US okay for first targeted bladder cancer drug

EU regulators to fast-track Janssen's multiple myeloma CAR-T

Fusion raises $105m for radiopharmaceutical trials

Third Rock in $2bn drug-hunting pact with China's Funnel

Securing your ROI: Turning post-acquisition integration into...

News

Editor's Picks